HomeComparePEXNY vs ABBV

PEXNY vs ABBV: Dividend Comparison 2026

PEXNY yields 5.93% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PEXNY wins by $136.92M in total portfolio value
10 years
PEXNY
PEXNY
● Live price
5.93%
Share price
$8.50
Annual div
$0.50
5Y div CAGR
76.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$137.02M
Annual income
$123,106,406.65
Full PEXNY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — PEXNY vs ABBV

📍 PEXNY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPEXNYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PEXNY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PEXNY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PEXNY
Annual income on $10K today (after 15% tax)
$504.27/yr
After 10yr DRIP, annual income (after tax)
$104,640,445.65/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, PEXNY beats the other by $104,619,389.65/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PEXNY + ABBV for your $10,000?

PEXNY: 50%ABBV: 50%
100% ABBV50/50100% PEXNY
Portfolio after 10yr
$68.56M
Annual income
$61,565,589.20/yr
Blended yield
89.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PEXNY
Analyst Ratings
3
Buy
Consensus: Buy
Altman Z
2.1
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PEXNY buys
0
ABBV buys
0
No recent congressional trades found for PEXNY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPEXNYABBV
Forward yield5.93%3.06%
Annual dividend / share$0.50$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR76.5%40.6%
Portfolio after 10y$137.02M$102.3K
Annual income after 10y$123,106,406.65$24,771.77
Total dividends collected$135.92M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: PEXNY vs ABBV ($10,000, DRIP)

YearPEXNY PortfolioPEXNY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,747$1,047.10$11,550$430.00+$197.00PEXNY
2$14,598$2,028.99$13,472$627.96+$1.1KPEXNY
3$19,780$4,159.26$15,906$926.08+$3.9KPEXNY
4$30,460$9,295.82$19,071$1,382.55+$11.4KPEXNY
5$56,206$23,613.56$23,302$2,095.81+$32.9KPEXNY
6$132,014$71,874.33$29,150$3,237.93+$102.9KPEXNY
7$419,724$278,468.36$37,536$5,121.41+$382.2KPEXNY
8$1,909,529$1,460,424.20$50,079$8,338.38+$1.86MPEXNY
9$13,002,994$10,959,798.00$69,753$14,065.80+$12.93MPEXNY
10$137,019,610$123,106,406.65$102,337$24,771.77+$136.92MPEXNY

PEXNY vs ABBV: Complete Analysis 2026

PEXNYStock

PTT Exploration and Production Public Company Limited, together with its subsidiaries, engages in the exploration and production of petroleum in Thailand and internationally. It is also involved in the gas pipeline transportation business; investment funding; and the provision of petroleum-related technology, human resource support, treasury center, technology, and solar power businesses, as well as renewable energy and related activities. In addition, the company invests in cleaner energy and technology-related businesses. The company was founded in 1985 and is headquartered in Bangkok, Thailand. PTT Exploration and Production Public Company Limited is a subsidiary of PTT Public Company Limited.

Full PEXNY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PEXNY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PEXNY vs SCHDPEXNY vs JEPIPEXNY vs OPEXNY vs KOPEXNY vs MAINPEXNY vs JNJPEXNY vs MRKPEXNY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.